PolyPid Appoints UCSF Brain Tumor Center Director Mitchel S. Berger, M.D., to Oncology Advisory Board
January 04, 2022 07:30 ET
|
PolyPid Ltd.
Dr. Berger Brings Extensive Expertise in Deep Brain Tumor Treatment The Company Expects to Initiate a Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors by the end of 2022 PETAH TIKVA, Israel,...
PolyPid Announces Planned CEO Transition
January 03, 2022 07:30 ET
|
PolyPid Ltd.
PETAH TIKVA, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a Phase 3 biopharmaceutical company focused on developing targeted, locally...
PolyPid Announces 500th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ in Abdominal Surgery
November 18, 2021 07:00 ET
|
PolyPid Ltd.
PETAH TIKVA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally...
PolyPid Appoints New Oncology Advisory Board Member
November 16, 2021 07:00 ET
|
PolyPid Ltd.
PETAH TIKVA, Israel, Nov. 16, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally...
PolyPid Ltd. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 10, 2021 07:00 ET
|
PolyPid Ltd.
Recruitment Progressing as Planned with Approximately 480 Patients Enrolled in Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery Following FDA Agreement that a Single Pivotal Phase 3 Study is...
PolyPid to Report Third Quarter 2021 Financial Results and Operational Highlights on November 10, 2021
November 01, 2021 07:00 ET
|
PolyPid Ltd.
PETAH TIKVA, Israel, Nov. 01, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally...
PolyPid to Present at Upcoming Cantor Fitzgerald Global Healthcare Conference
September 20, 2021 07:00 ET
|
PolyPid Ltd.
PETAH TIKVA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and...
PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer
September 13, 2021 07:30 ET
|
PolyPid Ltd.
Positive Results in Two Animal Models of Glioblastoma Multiform (GBM) demonstrated that Single Local Treatment of OncoPLEX Significantly Inhibited Tumor Growth and Prolonged SurvivalCompany Expects a...
PolyPid to Present at First World Association Against Infection in Orthopaedics and Trauma Congress
August 17, 2021 08:00 ET
|
PolyPid Ltd.
PETACH TIKVA, Israel, Aug. 17, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma focusing on developing targeted, locally administered and prolonged-release...
PolyPid Ltd. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 11, 2021 07:00 ET
|
PolyPid Ltd.
• Recruitment Progressing as Planned with Over 300 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery • FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for...